1 résultat
Paclitaxel-bevacizumab +/- atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial
Auteurs / Authors
E. Giroux-Leprieur; A. Scherpereel; L. Greillier; V. Gounant; S. Hiret; L. Bigay-Game; G. Pavaut; M. Zysman; C. Deldycke; E. Berton; S. Galland-Girodet; C. Guguen; C. Mascaux; S. Couraud; O. Bylicki; M. El Hajjam; P. Fournel; A. Langlais; F. Morin; V. Westeel.
Journal / Conference
ESMO
Année / Year
2025
PMID / session
Etude IFCT
